SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation

Table 1 Relationship between SPAG5 expression and clinicopathological features in 136 HCC patients

Parameters	Total case	SPAG5		P value
Parameters	136	High expression (N=93)	Low expression (N=43)
Age(years)				P=0.845
<60	87	60	27
≥60	49	33	16
Gender				P=0.939
Female	29	20	9
Male	107	73	34
Tumor size (cm)				*P<0.001*
<5	70	33	37
≥5	66	60	6
Tumor nodule number				P=0.499
Single	100	70	30
Multiple	36	23	13
HBsAg				P=0.939
Negative	29	20	9
Positive	107	73	34
AFP(ng/ml)				*P<0.001*
<400	39	6	33
≧400	97	87	10
Cirrhosis				P=0.601
Absence	108	75	33
Presence	28	18	10
Liver function				P=0.804
Child-Pugh A	109	74	35
Child-pugh B	27	19	8
Lobe				P=0.222
Right	95	68	27
Left	41	25	16
TNM				P=0.813
I/II	93	63	30
III/IV	43	30	13

ISSN: 1756-9966